news
Data from the Phase I study of collaborative industry partnership…
26 February 2018 | By Drug Target Review
Data from the Phase I study of collaborative industry partnership AMP are now available, meaning scientists can benefit from access to important research about Rheumatoid Arthritis and Systemic Lupus Erythematosus.